For how long should breastfeeding be avoided after completing oral terbinafine therapy?

Breastfeeding After Oral Terbinafine

You do not need to avoid breastfeeding after taking oral terbinafine, though the FDA-approved labeling notes that terbinafine passes into breast milk and could affect a nursing baby. The decision to breastfeed while on terbinafine should involve a discussion of risks and benefits with your physician 1.

Key Evidence and Reasoning

FDA Labeling Position

The FDA classifies terbinafine as pregnancy category B and acknowledges that terbinafine passes into breast milk 1, 2. However, the FDA labeling does not specify a mandatory waiting period after completing therapy before resuming breastfeeding. Instead, it emphasizes the need for individualized risk-benefit discussion between the patient and physician 1.

Clinical Context

The 2007 IDSA sporotrichosis guidelines specifically address this scenario, stating that pregnant patients and nursing mothers should discuss with their physicians the risks and benefits of taking terbinafine 1. This guideline acknowledges terbinafine's passage into breast milk but does not mandate complete avoidance or specify a waiting period after treatment completion.

Pharmacokinetic Considerations

Terbinafine has important pharmacokinetic properties relevant to breastfeeding:

• It is strongly lipophilic and distributes well into tissues 3
• It has a long half-life and persists in tissues (particularly nails) for months after treatment completion 3
• It is detected in nails within 1 week and persists for 6 months after completing treatment 3

This prolonged tissue persistence means that waiting days or even weeks after completing oral therapy would not eliminate terbinafine from the body or prevent its passage into breast milk.

Practical Recommendation

There is no evidence-based specific waiting period after completing terbinafine therapy before resuming breastfeeding. Given that:

1. Terbinafine persists in the body for months after treatment cessation
2. No specific washout period is recommended in FDA labeling or clinical guidelines
3. The drug's lipophilic nature means it will continue to be present in breast milk long after the last dose

The decision should be made based on:

• The necessity of the terbinafine treatment for the mother
• The age and health status of the infant (full-term vs. preterm, healthy vs. compromised)
• Alternative feeding options available
• The mother's clinical situation

Monitoring Recommendations

If breastfeeding continues during or after terbinafine therapy:

• Monitor the infant closely for gastrointestinal symptoms, rash, or other unusual signs 4
• Be aware that infants' metabolic and excretory capacities improve rapidly in the first months of life, so risk decreases with infant age 4
• Consider the infant's overall health status when making the decision

Important Caveats

• The evidence base for terbinafine and breastfeeding is limited, with no high-quality studies measuring infant exposure or outcomes
• The general principle for medications during lactation is to avoid breastfeeding when milk drug concentrations are at their peak (typically 1-2 hours after oral medication) 4, but this is impractical for a medication with such prolonged tissue persistence
• For life-threatening maternal infections requiring terbinafine, the benefits of treatment typically outweigh theoretical risks to the infant 1